Introduction
Primary cutaneous lymphomas are a heterogeneous group of lymphoid malignancies and are the second most common group of extranodal non-Hodgkin lymphomas (NHL) after gastrointestinal lymphomas. 1 NHL involving the female genitalia is unusual, posing diagnostic and therapeutic challenges. [2] [3] [4] Rare cases of vulvar NHL presenting as a vulvar mass have mostly been diagnosed as diffuse large B-cell lymphoma and have had an aggressive course. 3, 5 Cases of cutaneous T-cell lymphoma (CTCL) involving the vulva have been rarely reported. We have described the cases of 3 patients with mycosis fungoides (MF) tumors involving the labia majora and discussed our therapeutic approach.
Case Report
Vulvar involvement by MF in 3 consecutive female patients was recently diagnosed and treated in our institution.
Patient 1
The first patient was a 30-year-old woman with a 10-year history of MF stage IIA who had been previously treated with topical steroids, phototherapy, interferon, and local radiotherapy (RT). A partial response was achieved with oral bexarotene 450 mg daily until she presented with worsening of plaque disease on her skin and a rapidly growing tumor involving the external genitalia. The physical examination revealed pink to violaceous plaques with overlying scale on the extremities, buttocks, and vulva and a 2-cm tumor on her right labia majora ( Figure 1A) . A biopsy of the tumor revealed histopathologic findings consistent with tumor stage MF with monoclonal T-cell receptor gene rearrangements identical to those identified in a forearm MF lesion. The disease was considered stage IIB. CD30 staining of the tumor tissue highlighted larger lymphocytes; therefore, brentuximab vedotin treatment was initiated. However, only a partial response was achieved, and a new ulcerated tumor had developed on the left labia. The patient was referred for palliative electron beam RT to the left labia (14 Gy given in 7 fractions, with 2 fractions given each week) with a complete response, followed by total skin electron beam (TSEB) RT to the rest of her skin.
Patient 2
The second patient was an 85-year-old female patient with a 5-year history of stage IIB MF and large cell transformation who was in near-complete remission with maintenance therapy of oral bexarotene (150 mg/d) after TSEB therapy and additional radiation
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Involvement of the female external genitalia by cutaneous T-cell lymphoma and mycosis fungoides (MF) is rare and difficult to diagnose and treat. We report 3 consecutive cases of female patients with a history of MF who presented with new tumors involving the labia majora. In all cases, a painful genital tumor accompanied an exacerbation of extragenital diffuse plaque disease with an aggressive course.
All 3 patients were treated with localized electron or photon radiotherapy to the vulvar area (14-25 Gy given in 7-10 fractions) with an excellent local response. A vulvar tumor in a patient with known history of MF should raise a high suspicion for genital involvement by the disease, and skin biopsy should be considered.
doses to the perineum and gluteal folds. The patient developed recurrent patches and plaques on her trunk and extremities, and the bexarotene dose was increased to 300 mg/d. Two months later, the patient returned to our clinic complaining of a rapidly growing labial mass. Physical examination revealed erythematous plaques on her trunk and red-purple tumors involving the vulva ( Figure 1B) . A biopsy was performed from the labial mass, confirming the diagnosis of MF. The patient received photon RT to the vulvar area (25 Gy in 10 fractions given every other day) with an almost complete response and significant alleviation of her symptoms. However, shortly after the treatment was completed, the patient developed pneumonia and died.
Patient 3
The third patient was a 52-year-old woman in whom MF stage IIB had been diagnosed 3 years earlier. She had been treated with romidepsin, local RT, chemotherapy (gemcitabine/doxorubicin), oral bexarotene, brentuximab vedotin, and TSEB, with additional RT doses to the groin area. During maintenance bexarotene (300 mg/d) therapy, the patient complained of a new painful tumor on her labia. On physical examination, hyperpigmented and erythematous patches and plaques were seen on the trunk, extremities, and inguinal and intergluteal folds. On the right labia majora, a red tumor was present. Because of the clinical appearance, the patient was referred for localized RT. Before treatment, a positron emission tomography scan was performed, which showed increased cutaneous fluorodeoxyglucose-avid lesions in the gluteal and perineal areas ( Figure 1C ). The patient underwent electron beam RT (20 Gy in 10 fractions given every other day) to the right labia and intergluteal fold, with significant local improvement. The patient was enrolled in a clinical trial of an experimental targeted therapy, with initial improvement but eventual progression of generalized skin disease, although not in the genitalia.
Discussion
MF is an indolent NHL and the most common type of CTCL. It typically presents on sun-protected body areas, including the chest, inner arms, buttocks, lower trunk, and groin, 6 and involvement of the genitalia by MF has not been well characterized. The labia majora can be potentially involved by CTCL; however, only rare cases have been reported. All 3 of the present patients had had a long history of MF before presenting with a vulvar MF tumor. In addition, patients 2 and 3 had developed other tumors previously. Bakar et al 7 reported a woman in her 30s with a 7-year history of MF stage IA who presented with a new mass involving the left labia majora that was diagnosed as an MF tumor. The tumor appeared during the postpartum period and was successfully treated with low-dose intermittent local RT. 7 In another report, MF had initially been diagnosed in a woman in her 50s with a solitary labial swelling and no history of MF. The vulvar lesion was excised, with no evidence of recurrence. 8 Two patients had nontumorous MF vulvar lesions, presenting as a chronic fissure 9 and vulvar pruritus and dyspareunia. 3 Primary cutaneous anaplastic large cell lymphoma presenting as an ulcerated mass on the labia majora has also been reported. 10 That patient was treated with a short chemotherapy course and local RT, with a complete response. 10 Because of their rarity, lymphoma in general, and CTCL in particular, are not usually considered in the differential diagnosis of vulvar tumors. Also, inflammatory processes and other malignancies present more commonly on the external female genitalia. 3, 11 In a patient with CTCL with a history of a rapidly growing genital mass, vulvar involvement by cutaneous lymphoma should be considered and histologic confirmation obtained. CTCLs are highly radiosensitive, and localized RT is a very effective approach for localized or large plaques and tumor Radiotherapy for Vulvar MF Tumors nodules in both early-and advanced-stage MF. 12 For local palliation, doses from 8 to 30 Gy have been recommended to achieve a complete response, and a more advanced tumor stage and large cell transformation require the higher doses. The dose can be divided into fraction sizes of 3 to 5 Gy, which are generally very well tolerated. 13 A dose of 16 Gy in 8 fractions was given to a previously reported patient with vulvar MF tumor, with complete remission. 7 Male patients can also develop genital involvement by MF. In 1 case, a penile ulcerated MF lesion was treated with excision, local RT (27 Gy in 15 fractions), and systemic therapy, with a complete response.
14 In our case series, excellent results were achieved with localized RT to the vulvar area (14-25 Gy doses given in 7-10 fractions). In our patients, the vulvar tumors accompanied a flare of diffuse extragenital plaque disease. Despite the excellent local response to RT to the genital area, in 2 patients, the extragenital disease was resistant to therapy and progressed, and the third patient died of pneumonia shortly after RT. Although our case series was small, our findings support those from previous reports on aggressive disease in NHL involving the vulva. 3 However, larger series are needed to confirm this association.
Conclusion
MF patients should be routinely questioned about genital involvement, appropriate physical examination of the genital areas should be performed, and suspicious new lesions should be biopsied. Excellent local control can be achieved with lowdose RT.
